CY1124190T1 - Anti-ctla4 μονοκλωνικο αντισωμα ή το θραυσμα δεσμευσης αντιγονου αυτου, φαρμακευτικη συνθεση και χρηση - Google Patents
Anti-ctla4 μονοκλωνικο αντισωμα ή το θραυσμα δεσμευσης αντιγονου αυτου, φαρμακευτικη συνθεση και χρησηInfo
- Publication number
- CY1124190T1 CY1124190T1 CY20211100197T CY211100197T CY1124190T1 CY 1124190 T1 CY1124190 T1 CY 1124190T1 CY 20211100197 T CY20211100197 T CY 20211100197T CY 211100197 T CY211100197 T CY 211100197T CY 1124190 T1 CY1124190 T1 CY 1124190T1
- Authority
- CY
- Cyprus
- Prior art keywords
- monoclonal antibody
- antigen
- pharmaceutical composition
- binding fragment
- ctla4 monoclonal
- Prior art date
Links
- 239000012634 fragment Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 abstract 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 abstract 1
- 206010062016 Immunosuppression Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000001506 immunosuppresive effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70521—CD28, CD152
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Η παρούσα εφεύρεση ανήκει στα πεδία της θεραπείας όγκων και της μοριακής ανοσολογίας και παρέχει ένα αντι-CTLA4 μονοκλωνικό αντίσωμα ή το θραύσμα δέσμευσης αντιγόνου αυτού, μια φαρμακευτική σύνθεση του και τη χρήση του. Το μονοκλωνικό αντίσωμα της παρούσας εφεύρεσης μπορεί να εμποδίσει τη δέσμευση του CLTA4 στο Β7, να ανακουφίσει την ανοσοκαταστολή στο σώμα μέσω του CTLA4 και να ενεργοποιήσει τα Τ λεμφοκύτταρα.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410377352.9A CN105296433B (zh) | 2014-08-01 | 2014-08-01 | 一种ctla4抗体、其药物组合物及其用途 |
PCT/CN2015/085721 WO2016015675A1 (zh) | 2014-08-01 | 2015-07-31 | 抗ctla4的单克隆抗体或其抗原结合片段、药物组合物及用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1124190T1 true CY1124190T1 (el) | 2022-05-27 |
Family
ID=55194268
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20211100197T CY1124190T1 (el) | 2014-08-01 | 2021-03-08 | Anti-ctla4 μονοκλωνικο αντισωμα ή το θραυσμα δεσμευσης αντιγονου αυτου, φαρμακευτικη συνθεση και χρηση |
Country Status (40)
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105296433B (zh) * | 2014-08-01 | 2018-02-09 | 中山康方生物医药有限公司 | 一种ctla4抗体、其药物组合物及其用途 |
SI3303394T1 (sl) | 2015-05-29 | 2020-10-30 | Agenus Inc. | Protitelesa proti-CTLA-4 in postopki njihove uporabe |
KR102434314B1 (ko) | 2015-09-01 | 2022-08-19 | 아게누스 인코포레이티드 | 항-pd-1 항체 및 이를 이용하는 방법 |
JP7069032B2 (ja) | 2016-03-24 | 2022-05-17 | ミレニアム ファーマシューティカルズ, インコーポレイテッド | がん免疫治療における胃腸の免疫関連有害事象の治療方法 |
TW201735949A (zh) | 2016-03-24 | 2017-10-16 | 千禧製藥公司 | 治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法 |
CN107400166A (zh) | 2016-05-19 | 2017-11-28 | 苏州康宁杰瑞生物科技有限公司 | 针对ctla4的单域抗体及其衍生蛋白 |
CN109475603B (zh) | 2016-06-20 | 2023-06-13 | 科马布有限公司 | 抗pd-l1抗体 |
WO2018035710A1 (en) | 2016-08-23 | 2018-03-01 | Akeso Biopharma, Inc. | Anti-ctla4 antibodies |
CN106967172B (zh) * | 2016-08-23 | 2019-01-08 | 康方药业有限公司 | 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途 |
CN110035773B (zh) * | 2016-10-10 | 2023-06-02 | 中美冠科生物技术(太仓)有限公司 | 新型抗ctla4抗体 |
WO2018071500A1 (en) | 2016-10-11 | 2018-04-19 | Agenus Inc. | Anti-lag-3 antibodies and methods of use thereof |
HRP20231579T1 (hr) | 2016-12-07 | 2024-03-15 | Agenus Inc. | Anti-ctla-4 antitijela i postupci njihove upotrebe |
WO2018165895A1 (zh) * | 2017-03-15 | 2018-09-20 | 苏州银河生物医药有限公司 | Ctla4抗体、其药物组合物及其用途 |
JP2020512354A (ja) * | 2017-03-31 | 2020-04-23 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | Pd−1のアンタゴニストと抗ctla4抗体との組み合わせでがんを処置するための組成物および方法 |
AU2018263837A1 (en) * | 2017-05-02 | 2019-12-05 | Merck Sharp & Dohme Llc | Stable formulations of anti-CTLA4 antibodies alone and in combination with programmed death receptor 1 (PD-1) antibodies and methods of use thereof |
JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
CN110913906A (zh) | 2017-05-02 | 2020-03-24 | 默沙东公司 | 抗lag3抗体的制剂和抗lag3抗体与抗pd-1抗体的共制剂 |
EA201992755A1 (ru) * | 2017-05-19 | 2020-04-22 | Уси Байолоджикс (Шанхай) Ко. Лтд. | Новые моноклональные антитела к белку 4, ассоциированному с цитотоксическими т-лимфоцитами, (ctla-4) |
CN108948194B (zh) * | 2017-05-19 | 2023-02-17 | 上海药明生物技术有限公司 | 一种新的ctla-4单克隆抗体 |
AR111760A1 (es) | 2017-05-19 | 2019-08-14 | Novartis Ag | Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral |
CN107325181A (zh) * | 2017-07-05 | 2017-11-07 | 无锡傲锐东源生物科技有限公司 | 抗ctla4蛋白单克隆抗体及其用途 |
WO2019036855A1 (en) | 2017-08-21 | 2019-02-28 | Adagene Inc. | ANTI-CD137 MOLECULES AND THEIR USE |
WO2019056281A1 (en) * | 2017-09-21 | 2019-03-28 | Eucure (Beijing) Biopharma Co., Ltd | ANTI-CTLA4 ANTIBODIES AND USES THEREOF |
WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
WO2019148444A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anti-ctla4 antibodies and methods of making and using the same |
EP3752193A4 (en) * | 2018-02-13 | 2022-02-23 | Merck Sharp & Dohme Corp. | METHODS OF TREATING CANCER WITH ANTI PD-1 ANTIBODIES AND ANTI CTLA4 ANTIBODIES |
CN112218892B (zh) * | 2018-03-19 | 2023-04-25 | 上海药明生物技术有限公司 | 新型抗ctla-4抗体多肽 |
CN109336975B (zh) * | 2018-04-18 | 2022-05-13 | 中国科学院微生物研究所 | 一种靶向pd-1的肿瘤抑制性抗体及其应用 |
CN115991787A (zh) * | 2018-06-05 | 2023-04-21 | 江苏康宁杰瑞生物制药有限公司 | 二聚体及其用途 |
CA3103629A1 (en) | 2018-06-15 | 2019-12-19 | Flagship Pioneering Innovations V, Inc. | Increasing immune activity through modulation of postcellular signaling factors |
CN110760002A (zh) * | 2018-07-25 | 2020-02-07 | 南京金斯瑞生物科技有限公司 | 人源化抗人ctla4单克隆抗体及其制备方法和用途 |
AU2019407814A1 (en) | 2018-12-21 | 2021-07-22 | Ose Immunotherapeutics | Bifunctional anti-PD-1/IL-7 molecule |
WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
WO2020227159A2 (en) | 2019-05-03 | 2020-11-12 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity |
CN110256561B (zh) * | 2019-06-13 | 2021-04-16 | 东大生物技术(苏州)有限公司 | 一组ctla-4单克隆抗体及其医药用途 |
CN110256563A (zh) * | 2019-07-05 | 2019-09-20 | 石河子大学 | Ctla-4纳米抗体、制备方法及其应用 |
WO2021127217A1 (en) | 2019-12-17 | 2021-06-24 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
AU2020406083A1 (en) | 2019-12-17 | 2022-06-16 | Ose Immunotherapeutics | Bifunctional molecules comprising an IL-7 variant |
EP4114863A4 (en) * | 2020-03-05 | 2024-04-24 | Merck Sharp & Dohme Llc | METHODS OF TREATING CANCER OR INFECTION USING A COMBINATION OF AN ANTI-PD-1 ANTIBODY, AN ANTI-CTLA4 ANTIBODY AND AN ANTI-TIGIT ANTIBODY |
CN115443291A (zh) * | 2020-04-13 | 2022-12-06 | 博奥信生物技术(南京)有限公司 | 结合ctla4的抗体及其用途 |
JP2023532339A (ja) | 2020-06-29 | 2023-07-27 | フラグシップ パイオニアリング イノベーションズ ブイ,インコーポレーテッド | サノトランスミッションを促進するためにエンジニアリングされたウイルス及び癌の処置におけるそれらの使用 |
CN113980130B (zh) * | 2020-07-27 | 2023-07-21 | 湖南远泰生物技术有限公司 | 人源化cd37和双特异性cd19-人源化cd37 car-t细胞 |
CN112079926A (zh) * | 2020-09-17 | 2020-12-15 | 北京华大蛋白质研发中心有限公司 | 抗人ctla4单克隆抗体及其应用 |
WO2022112198A1 (en) | 2020-11-24 | 2022-06-02 | Worldwide Innovative Network | Method to select the optimal immune checkpoint therapies |
EP4313109A1 (en) | 2021-03-31 | 2024-02-07 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
IL307419A (en) | 2021-04-09 | 2023-12-01 | Ose Immunotherapeutics | A new scaffold for bifunctional molecules with improved properties |
WO2022214652A1 (en) | 2021-04-09 | 2022-10-13 | Ose Immunotherapeutics | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains |
CA3224374A1 (en) | 2021-06-29 | 2023-01-05 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
WO2023143597A1 (en) * | 2022-01-30 | 2023-08-03 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Anti-ctla4/ox40 bispecific antibodies and uses thereof |
WO2024003360A1 (en) | 2022-07-01 | 2024-01-04 | Institut Curie | Biomarkers and uses thereof for the treatment of neuroblastoma |
WO2024028386A1 (en) | 2022-08-02 | 2024-02-08 | Ose Immunotherapeutics | Multifunctional molecule directed against cd28 |
WO2024056049A1 (zh) * | 2022-09-16 | 2024-03-21 | 同润生物医药(上海)有限公司 | 具有pH依赖性的抗CTLA4抗体或抗原结合片段 |
WO2024077191A1 (en) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US682736A (en) | 1900-08-02 | 1901-09-17 | James C Owen | Oil-can. |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5851795A (en) * | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
US6719972B1 (en) | 1994-06-03 | 2004-04-13 | Repligen Corporation | Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies |
KR19990008070A (ko) | 1995-04-27 | 1999-01-25 | 게일 케이.노톤 | 합성 또는 천연 혈관 식피의 멸균, 내이식, 배양, 보존, 수송및 검사를 위한 장치 및 방법 |
US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
JP2001523958A (ja) | 1997-03-21 | 2001-11-27 | ブライハム アンド ウィミンズ ホスピタル,インコーポレイテッド | 免疫療法のctla−4結合ペプチド |
US7122615B1 (en) | 1998-09-10 | 2006-10-17 | Rutgers, The State University Of New Jersey | Polyanhydrides with therapeutically useful degradation products |
RS51309B (sr) | 1998-12-23 | 2010-12-31 | Pfizer Inc. | Humana monoklonalna antitela za ctla-4 |
US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
EP1792991A1 (en) | 1999-08-24 | 2007-06-06 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
US7034121B2 (en) | 2000-01-27 | 2006-04-25 | Genetics Institue, Llc | Antibodies against CTLA4 |
IL149701A0 (en) | 2001-05-23 | 2002-11-10 | Pfizer Prod Inc | Use of anti-ctla-4 antibodies |
EP1503794B9 (en) | 2002-04-12 | 2012-09-19 | Medarex, Inc. | Methods of treatement using ctla-4 antibodies |
EP2484660A3 (en) | 2002-05-24 | 2013-03-13 | Castrol Limited | Preparation of monomers for grafting to polyolefins |
ATE481985T1 (de) | 2002-07-03 | 2010-10-15 | Ono Pharmaceutical Co | Immunpotenzierende zusammensetzungen |
EP1549678A4 (en) | 2002-09-30 | 2006-01-18 | Pfizer Prod Inc | HYBRIDOMAS THAT PRODUCE HIGH CONCENTRATIONS OF ANTIBODIES TO THE HUMAN SEQUENCE |
US8168170B2 (en) | 2002-10-03 | 2012-05-01 | The Procter And Gamble Company | Compositions having an inner core and at least three surrounding layers |
US7465446B2 (en) | 2003-05-30 | 2008-12-16 | Medarex, Inc. | Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease |
KR100845354B1 (ko) | 2004-03-26 | 2008-07-09 | 화이자 프로덕츠 인코포레이티드 | 항-ctla-4 항체의 용도 |
DE102004063494A1 (de) * | 2004-12-23 | 2006-07-13 | Tegenero Ag | Antikörper |
AR053553A1 (es) | 2005-03-08 | 2007-05-09 | Pharmacia & Upjohn Co Llc | Composicion de anticuerpos anti molecula de adhesion celular adresina mucosa (anti-madcam) |
CA2604877A1 (en) | 2005-04-11 | 2006-10-19 | J.P. Sercel Associates Inc. | Protein purification |
SI2439273T1 (sl) | 2005-05-09 | 2019-05-31 | Ono Pharmaceutical Co., Ltd. | Človeška monoklonska protitelesa za programirano smrt 1 (PD-1) in postopki za zdravljenje raka z uporabo protiteles proti PD-1 samostojno ali v kombinaciji z ostalimi imunoterapevtiki |
WO2007113648A2 (en) | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
CN101074264B (zh) * | 2006-05-17 | 2011-08-17 | 上海抗体药物国家工程研究中心有限公司 | 一种重组抗ctla4单克隆抗体及其制备方法和用途 |
EP2240204A1 (en) | 2008-02-04 | 2010-10-20 | Medarex, Inc. | Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof |
US9540426B2 (en) | 2009-10-06 | 2017-01-10 | Bristol-Myers Squibb Company | Mammalian cell culture processes for protein production |
BR112012008665A2 (pt) | 2009-10-12 | 2016-11-22 | Pfizer | tratamento de câncer |
PL2501822T3 (pl) | 2009-11-17 | 2017-12-29 | E. R. Squibb & Sons, L.L.C. | Sposoby zwiększenia produkcji białek |
CN102134276A (zh) * | 2010-01-22 | 2011-07-27 | 上海抗体药物国家工程研究中心有限公司 | 一种抗ctla-4嵌合抗体 |
CN103221544A (zh) * | 2010-09-24 | 2013-07-24 | 昂克斯治疗有限公司 | 编码单克隆抗-ctla-4抗体的溶瘤腺病毒载体 |
GB201103955D0 (en) * | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
AU2012275133B2 (en) | 2011-06-30 | 2017-08-17 | Genzyme Corporation | Inhibitors of T-cell activation |
US20150079100A1 (en) | 2012-03-23 | 2015-03-19 | Bristol-Myers Squibb Company | Methods of treatments using ctla-4 antibodies |
JP6448533B2 (ja) | 2012-05-15 | 2019-01-09 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Pd−1/pd−l1シグナル伝達を破壊することによる癌免疫療法 |
US8844207B2 (en) | 2012-06-04 | 2014-09-30 | Mity-Lite, Inc. | Portable dance floor panel with floating magnet retention system |
CN102801616B (zh) | 2012-08-02 | 2015-04-15 | 华为技术有限公司 | 报文发送和接收的方法、装置和*** |
EP2759305A1 (en) | 2013-01-24 | 2014-07-30 | Thrombotargets Europe, S.L. | Hemostatic compositions |
EP3049442A4 (en) | 2013-09-26 | 2017-06-28 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
EP3572430A3 (en) | 2014-03-05 | 2020-02-12 | Bristol-Myers Squibb Company | Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent |
EP3760229A3 (en) | 2014-05-15 | 2021-04-07 | Bristol-Myers Squibb Company | Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent |
CN105296433B (zh) * | 2014-08-01 | 2018-02-09 | 中山康方生物医药有限公司 | 一种ctla4抗体、其药物组合物及其用途 |
US20180133313A1 (en) | 2014-12-16 | 2018-05-17 | Bristol-Myers Squibb Company | Use of immune checkpoint inhibitors in central nervous systems neoplasms |
CN104479019B (zh) | 2014-12-26 | 2020-07-21 | 上海复宏汉霖生物技术股份有限公司 | 一种抗ctla-4人源抗体 |
SG10202006863YA (en) | 2015-02-16 | 2020-08-28 | Lonza Ag | Cl and/or ch1 mutated antibodies for drug conjugation |
WO2016183469A1 (en) | 2015-05-13 | 2016-11-17 | Robert Kirken | Anti-ctla-4 blockade |
WO2017132508A1 (en) | 2016-01-27 | 2017-08-03 | Bristol-Myers Squibb Company | Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent |
-
2014
- 2014-08-01 CN CN201410377352.9A patent/CN105296433B/zh active Active
-
2015
- 2015-07-31 AU AU2015295936A patent/AU2015295936C1/en active Active
- 2015-07-31 LT LTEP15827441.5T patent/LT3176181T/lt unknown
- 2015-07-31 AP AP2017009762A patent/AP2017009762A0/en unknown
- 2015-07-31 EA EA201790288A patent/EA036396B1/ru not_active IP Right Cessation
- 2015-07-31 KR KR1020177005688A patent/KR102017396B1/ko active IP Right Grant
- 2015-07-31 PL PL15827441T patent/PL3176181T3/pl unknown
- 2015-07-31 UA UAA201701943A patent/UA119570C2/uk unknown
- 2015-07-31 MA MA40474A patent/MA40474B1/fr unknown
- 2015-07-31 CN CN201580040171.XA patent/CN106687479B/zh active Active
- 2015-07-31 ES ES15827441T patent/ES2857509T3/es active Active
- 2015-07-31 US US15/500,744 patent/US10449251B2/en active Active
- 2015-07-31 EP EP15827441.5A patent/EP3176181B1/en active Active
- 2015-07-31 SI SI201531555T patent/SI3176181T1/sl unknown
- 2015-07-31 JP JP2017525666A patent/JP6514774B2/ja active Active
- 2015-07-31 CN CN202211206595.7A patent/CN115960232A/zh active Pending
- 2015-07-31 WO PCT/CN2015/085721 patent/WO2016015675A1/zh active Application Filing
- 2015-07-31 MA MA055868A patent/MA55868A/fr unknown
- 2015-07-31 EP EP20216429.9A patent/EP3858861A1/en active Pending
- 2015-07-31 NZ NZ729158A patent/NZ729158A/en unknown
- 2015-07-31 TN TN2017000010A patent/TN2017000010A1/en unknown
- 2015-07-31 SG SG11201700819QA patent/SG11201700819QA/en unknown
- 2015-07-31 BR BR112017002080-7A patent/BR112017002080A2/pt active Search and Examination
- 2015-07-31 MX MX2017001446A patent/MX2017001446A/es unknown
- 2015-07-31 MY MYPI2017000162A patent/MY192822A/en unknown
- 2015-07-31 PT PT158274415T patent/PT3176181T/pt unknown
- 2015-07-31 DK DK15827441.5T patent/DK3176181T3/da active
- 2015-07-31 MD MDA20170022A patent/MD4795C1/ro active IP Right Grant
- 2015-07-31 GE GEAP201514437A patent/GEP20207166B/en unknown
- 2015-07-31 HU HUE15827441A patent/HUE053719T2/hu unknown
- 2015-07-31 CA CA2956000A patent/CA2956000C/en active Active
- 2015-07-31 RS RS20210312A patent/RS61590B1/sr unknown
- 2015-07-31 PE PE2017000155A patent/PE20170772A1/es unknown
- 2015-08-31 CR CR20170033A patent/CR20170033A/es unknown
-
2017
- 2017-01-23 ZA ZA2017/00528A patent/ZA201700528B/en unknown
- 2017-01-26 IL IL250321A patent/IL250321B/en active IP Right Grant
- 2017-01-27 CO CONC2017/0000754A patent/CO2017000754A2/es unknown
- 2017-01-31 NI NI201700008A patent/NI201700008A/es unknown
- 2017-01-31 CL CL2017000250A patent/CL2017000250A1/es unknown
- 2017-01-31 MX MX2021013586A patent/MX2021013586A/es unknown
- 2017-01-31 PH PH12017500190A patent/PH12017500190A1/en unknown
- 2017-02-01 DO DO2017000031A patent/DOP2017000031A/es unknown
- 2017-03-01 EC ECIEPI201712781A patent/ECSP17012781A/es unknown
-
2018
- 2018-10-11 AU AU2018247270A patent/AU2018247270A1/en not_active Abandoned
-
2019
- 2019-02-28 JP JP2019036646A patent/JP6783886B2/ja active Active
- 2019-09-05 US US16/562,236 patent/US11291720B2/en active Active
-
2021
- 2021-03-08 CY CY20211100197T patent/CY1124190T1/el unknown
- 2021-03-17 HR HRP20210448TT patent/HRP20210448T1/hr unknown
-
2022
- 2022-03-15 US US17/695,592 patent/US20230064544A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1124190T1 (el) | Anti-ctla4 μονοκλωνικο αντισωμα ή το θραυσμα δεσμευσης αντιγονου αυτου, φαρμακευτικη συνθεση και χρηση | |
CY1123977T1 (el) | Anti-pd-1 και anti-lag3 αντισωματα για την θεραπεια του καρκινου | |
CY1125260T1 (el) | Παραγοντες δεσμευσης tigit και χρησεις τους | |
CY1124791T1 (el) | Μορια δεσμευσης ειδικα για cd73 και χρησεις αυτων | |
EA201892294A1 (ru) | Антитела и композиции против tim-3 | |
CY1121893T1 (el) | Μορια αντισωματος κατα της τιμ-3 και χρησεις αυτων | |
CL2017003261A1 (es) | Factor xi anticuerpos y métodos de uso | |
PE20171180A1 (es) | Anticuerpos anti-pd-1 y sus metodos de uso | |
EA201790545A1 (ru) | Антитела и иммуноконъюгаты против her2 | |
EA201790755A1 (ru) | Модуляция стимулирующих и нестимулирующих миелоидных клеток | |
EA201790569A1 (ru) | Антитела и иммуноконъюгаты против cll-1 | |
EA201692039A1 (ru) | ИММУНОГЛОБУЛИНЫ, СВЯЗЫВАЮЩИЕ ЧЕЛОВЕЧЕСКИЕ Vγ9Vδ2 Т-КЛЕТОЧНЫЕ РЕЦЕПТОРЫ | |
PE20190737A1 (es) | Anticuerpos anti-cd27 | |
PH12017500002A1 (en) | Anti-cdh6 antibody drug conjugates | |
PH12016502061A1 (en) | Novel antii-rnf43 antibodies and methods of use | |
NZ723858A (en) | Anti-human ox40l antibodies, uses & methods | |
EA201791049A1 (ru) | Комбинация анти-cs1 и анти-pd1 антител для лечения рака (миеломы) | |
BR112016029935A2 (pt) | ?anticorpos anti-brdu, complexo, formulação farmacêutica e uso de anticorpo? | |
DK3619237T3 (da) | Antistoffer mod karcinoembryonalt antigen til cancerterapi og -diagnosticering | |
EA201692560A1 (ru) | Моноклональные антитела против эпитопа her2 и способы их применения | |
EA202092450A2 (ru) | Комбинирование anti-lag-3-антител и анти-pd-1-антител для лечения опухолей | |
EA201792460A1 (ru) | Связывающие tigit агенты и варианты их применения |